Is this message not displayed correctly?
Please click here for the online version.
|
|
Dear Ms Hecht,
The German capital region, HealthCapital Berlin-Brandenburg, has developed into a vibrant center for global health innovations. This is evidenced by international organizations based in Berlin, conferences, and key trade fairs, as well as the multitude of international companies that are drawn to the city.
This year's World Health Summit (WHS) in Berlin, with 3,500 participants from 140 countries, once again provided the platform where leading minds and innovative ideas came together in Berlin. In recent years, it has established itself as the central platform and inclusive forum where the future of global healthcare is being shaped.
A special highlight was the announcement of the new program "WomenX Collective" by the UN Population Fund (UNFPA). Together with Charité – Universitätsmedizin Berlin and the Berlin Institute of Health at Charité (BIH), it is launching the first hub in a planned global network of centers focused on promoting women's health, particularly sexual and reproductive health. Berlin offers an excellent ecosystem for health and innovation, making it an ideal location for the project.
In addition to the WomenX Collective Hub, the Global Health Hub is a leading global network that cements our city’s position as a global hub in healthcare. And for three years now, the WHO Hub for Pandemic and Epidemic Intelligence has been an established global network node in Berlin. It has initiated important projects to strengthen emergency preparedness and response in the field of global health, which our current portrait reports on.
These and our other topics today demonstrate that the capital aims to take on and can take a leading role internationally. However, this is only possible with good cooperation partners from around the world.
Join us.
Your
Dr. Kai Uwe Bindseil
Berlin Partner for Business and Technology
|
|
New! Life Sciences Report 2024/2025
Our newest Life Sciences Report for Berlin-Brandenburg offers an impressive overview of the region's dynamic and innovative ecosystem. It highlights six key areas with particularly strong research and translation activities. Click here for the life sciences directory with over 760 stakeholders in the region. Download
|
|
|
The Digital Health Ecosystem Berlin-Brandenburg
An Insight Report
The Cluster Healthcare Industry Berlin-Brandenburg - HealthCapital has conducted an inventory of the digital health ecosystem in the capital region. Together with digital health experts, representative players, network and event formats as well as technology projects in the capital region were examined and the location's success factors for digital health innovations were identified.
Download
|
|
|
A better future for women's health Berlin will be the first hub of WomenX Collective – a new global center for advancing research, innovation and investment in women's health. This initiative aims to bridge the gap in women's health solutions by fostering stronger partnerships and rallying resources to promote gender equality in science, technology, and finance.
Dr Nigina Muntean, head of the Innovation Unit at the United Nations Population Fund (UNFPA), co-founded WomenX Collective. |
|
|
WHO Hub for Pandemic and Epidemic Intelligence – Supporting countries to make better decisions for public health emergencies At the WHO Hub for Pandemic and Epidemic Intelligence, an international team of scientists and public health experts work to protect communities - across the world and here in Germany - from health emergencies, in particular from the impacts of epidemics and pandemics. |
|
|
Not just in October – these players from the capital region Berlin help breast cancer patients October is Breast Cancer Awareness Month – a fact that goes back to an initiative by the American Cancer Society in the 1980s. The capital region Berlin is home to a large number of research and treatment institutions as well as companies dedicated to the prevention and treatment of breast cancer and patient support. |
|
|
Cambrium: New materials with the aid of AI The Berlin-based start-up Cambrium uses artificial intelligence to produce new bio-based and sustainable materials. The company is currently focusing on the production of proteins - primarily collagen. Further use cases are planned. |
|
|
Connected, comprehensive and always available – the future of health data Prof. Dr Martin Gersch holds a professorship in business administration at Freie Universität Berlin and also represents the FU Berlin on the steering committee of the “Health-X dataLOFT” lighthouse project. Together with partners from the German capital region Berlin Brandenburg, the project is developing solutions to create a “citizen-centered health data space” at European level. In this context, the Gersch working group at the FU Berlin is focusing on supporting the economic utilization and sustainable use of this emerging common data space. We spoke to Prof. Gersch about the progress of the project and the opportunities it offers. |
|
|
Strategic innovation for more progress in gene and cell therapy The National Strategy for Gene and Cell Therapies (GCT) has been moderated by the Berlin Institute of Health at Charité (BIH) in a multi-stakeholder process on behalf of the Federal Ministry of Education and Research (BMBF) since 2022. The National Network Office for Gene and Cell Therapies was established in October 2023 to build up a national GCT community independently and sustainably. We spoke to its director,
Dr Elke Luger, about the office's tasks, goals and challenges. |
|
|
The tip from our relocation experts
Special Tip: Mass Spectrometry Mass spectrometry is becoming essential in healthcare and Berlin offers an ideal setting for its development. The city hosts numerous research institutes and core facilities dedicated to mass spectrometry and related analytical technologies, fostering strong collaboration between academia and industry. |
|
|
Thanks to close proximity to major hospitals, Berlin’s mass spectrometry research is quickly moving into clinical applications. High-throughput analytics, such as liquid biopsies for cancer screening, spatial proteomics or single-cell proteomics analysis, are enhancing diagnostics and accelerating therapeutic developments. This close integration with healthcare providers positions Berlin as a leader in translating scientific breakthroughs into healthcare solutions. Supporting this landscape, Berlin’s hubs - especially Berlin-Buch and Adlershof - feature a concentration of analytical service providers focused on biopharmaceutical applications, making it an ideal ecosystem for startups in advanced diagnostics. For a closer look, our Life Science Report highlights Berlin’s mass spectrometry strengths, and our Life Science Directory provides a comprehensive view of key players in the region. Interested in establishing your mass spectrometry venture here? Connect with us to discover how Berlin Partner can support your growth! Kerem Can Akkaya Manager Biotech | Pharma Berlin Partner for Business and Technology 📧 |
|
|
|
|
Bayer's Expert Mondays 2024 - Ingredients to Successful Partnerships with Bayer
09 December 2024 | online
Read more
|
|
18th Annual European Life Sciences CEO Forum (ELSF)
26/27 February 2025 | Zurich, Switzerland
Read more |
|
RegMed Forum
27 February 2025 | Berlin, Germany
Read more |
|
BIO-Europe Spring 2025
17-19 March 2025 | Milan, Italy
Read more |
|
DMEA
08-10 April 2025 | Berlin, Germany
Read more |
|
BIONNALE
14-15 May 2025 | Berlin, Germany
Read more |
|
GITEX Europe 2025
21-23 May 2025 | Berlin, Germany
The Enterprise Europe Network Berlin-Brandenburg organizes a match-making event @GITEX EUROPE that brings together companies (buyers as well as suppliers) from a large number of European countries.
More information about the matchmaking event and registration:
GITEX 2025 - Info |
|
For more events in the life science region Berlin-Brandenburg click here. |
|
Berlin-based Neurotech startup Nuuron secures investment for the development of a digital drug to treat Alzheimer’s Disease Nuuron has raised €3.5 million in an oversubscribed seed financing round. The round is led by High-Tech Gründerfonds (HTGF) and includes investors such as IBB Ventures, caesar., the Business Angel Club Berlin, other business angels and family offices. In addition, Nuuron entered a strategic partnership with RoX Health, a subsidiary of the pharma and diagnostics group Roche.
|
|
|
Noah Labs receives
€3 million in financing round lead by Nina Capital Noah Labs, a Berlin and Potsdam-based digital health startup focused on AI-powered telemonitoring for patients with heart failure, has successfully closed a seed funding round of
€3 million. Lead investor Nina Capital from Barcelona a dedicated health technology investor. Co-investors include adesso ventures and the Foundation of the German Heart Center Berlin (DHZB). Additionally, the Brandenburg Investment Bank's funding program ProFIT Brandenburg funding program contributes with a grant and a loan to the financing as well as a range of business angels.
|
|
|
Formo bags $61 million in Series B funding - launches the world’s first animal-free cheese made with Koji Protein
German food fermentation startup Formo has secured $61 million in Series B funding to scale its operations. The round includes existing investors, such as Foodlabs, EQT Ventures, Lowercarbon Capital, Happiness Capital, Elevat3 Capital, M Ventures and Grazia Capital, and welcomes new investors, such as Sazaby League, Seven Ventures, Woodline Partners, Indiposa Investments, The Nature Conservancy as well as the REWE Group, Europe's second largest retailer.
Read more |
|
Aignostics secures $34M Series B to enhance precision medicine with AI
|
|
mediaire transforms radiology with AI, securing a European €12 million investment to fuel global growth
|
|
Vara Raises $8.9M in Funding While Expanding AI-Enabled Early Breast Cancer Detection to India
|
|
Pentixapharm Holding AG Completes IPO in the Prime Standard of the Frankfurt Stock Exchange
|
|
Eckert & Ziegler and GlyTherix Sign Agreement for Lutetium-177 Su
|
|
Science and Technology News
|
|
|
Impressive results against autoimmune disease The team at Charité – Universitätsmedizin Berlin is astounded by the huge improvement seen in a female patient with severe systemic lupus erythematosus (SLE) after being treated with the cancer medication teclistamab. Not long ago, the 23-year-old was wheelchair-bound due to the autoimmune disease. Nearly six months after starting treatment, the patient is now completely symptom-free. Only time will tell if this improvement will last over the long term, but the case – which the team has now published in the New England Journal of Medicine* – marks a promising starting point for further studies.
|
|
|
New regulator of glucose transport in adipose tissue discovered The role of the adapter protein Picalm in the development of Alzheimer's disease is well known. Now, researchers from the German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), the German Center for Diabetes Research (DZD), ETH Zurich, and the University of Cambridge have, for the first time, investigated Picalm's function in white fat tissue and its significance for metabolic health. They demonstrated that reduced Picalm expression improves insulin sensitivity and glucose transport in fat cells. These findings, recently published in Molecular Metabolism, could help to develop new therapeutic approaches for treating type 2 diabetes and obesity.
|
|
|
Gut microbiome influences location of immune cells Researchers at the Experimental and Clinical Research Center of Max Delbrück Center and Charité – Universitätsmedizin Berlin (ECRC) have found that different anatomical sections of the gastrointestinal tracts of mice carry different compositions of microbial communities. Moreover, the specific makeup of the microbiota can influence the type and abundance of immune cells in any particular region. The study, which was published in “Gut Microbes,” maps the complex spatial organization of immune cells and microbial communities, providing a tool for studying the interaction between gut microbes and inflammatory diseases. |
|
|
A new drug target for psychiatric disorders
|
|
New study: Mental Health in Real Time
|
|
Biomarker indicates response to immune system modulator therapy in advance
Read more |
|
A New Perspective on Aging at the Cellular Level
Read more |
|
Technology and Cooperation Offers
|
|
|
Small molecule inhibitors of STOML3 promise to treat neuropathic pain
Read more |
|
HSV signature antibodies predict the development of anti-NMDA receptor encephalitis
Read more |
|
Base Editing Enzymes for Multiplex Editing with Simultaneous Gene Knock-In and Knock-Ou
Read more |
|
An engineered serine integrase for targeted gene transfer in human cells
Read more |
|
For more news from the cluster healthcare industries click here. |
|
EDITOR | IMPRINT
This newsletter is operated by the cluster healthcare industries
Berlin-Brandenburg HealthCapital.
Berlin Partner for Business and Technology
Fasanenstrasse 85 | 10623 Berlin | Germany
Phone: +49 30 46302-463
Email: healthcapital@berlin-partner.de
Commercial Registry Entry
Entered in the commercial registry of the Charlottenburg District Court,
Registration number: HRB 13072 B
VAT ID: DE 136629780
CEO: Dr. Stefan Franzke
Chairman of the Supervisory Board: Carsten Jung
Editorial: In cooperation with dpa-Custom Content.
Responsible body in terms of German Press Law
Carolin Meltendorf, Press Spokeswoman Berlin Partner for Business and Technology
© 2024 Berlin Partner for Business and Technology |
|
The newsletter of the Cluster healthcare industries Berlin-Brandenburg is a project of Berlin Partner for Business and Technology.
|
|
|
You have been forwarded this newsletter and would like to subscribe?
Please click here.You want to unsubscribe from the newsletter (to: anika.hecht@berlin-partner.de)? Please click here.
|
|
|
|
|
